Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208274 | SCV000263898 | likely pathogenic | Marfan syndrome | 2015-09-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002426976 | SCV002742695 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2019-09-03 | criteria provided, single submitter | clinical testing | The p.G899R variant (also known as c.2695G>A), located in coding exon 22 of the FBN1 gene, results from a G to A substitution at nucleotide position 2695. The glycine at codon 899 is replaced by arginine, an amino acid with dissimilar properties. This variant was reported in a Korean Marfan syndrome (MFS) cohort in one individual who had a clinical diagnosis of MFS and who had two affected family members; however, clinical details were limited (Shin MS et al. Korean Circ J., 2003;33(11):1018-1027). Two other variants at this codon, p.G899R (c.2695G>C) and p.G899E (c.2696G>A), have also been associated with MFS, although clinical details were limited (Groth KA et al. Genet. Med., 2017 07;19:772-777; Seo GH et al. Medicine (Baltimore), 2018 May;97:e10767). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |